The Small Molecules Targeting Ubiquitin-Proteasome System for Cancer Therapy.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Combinatorial chemistry & high throughput screening

• Publication date

  2017-05-31

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/1386207320666170710124746PMID 28699494
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death*

  2016cited by this paper
• Clinical Overview of MDM2/X-Targeted Therapies

  2016cited by this paper
• Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells

  2015cited by this paper
• Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells

  2015cited by this paper
• Targeting the ubiquitin pathway for cancer treatment.

  2015cited by this paper
• Deubiquitinase inhibition by WP1130 leads to ULK1 aggregation and blockade of autophagy

  2015cited by this paper
• Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma

  2015cited by this paper
• Ubiquitylation, neddylation and the DNA damage response

  2015cited by this paper
• Targeting ubiquitination for cancer therapies.

  2015cited by this paper
• Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer.

  2014cited by this paper
• Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.

  2014cited by this paper
• A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.

  2014cited by this paper
• The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

  2014cited by this paper
• Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer

  2014cited by this paper
• SCF ubiquitin ligase-targeted therapies

  2014cited by this paper
• Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.

  2014cited by this paper
• Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer.

  2014cited by this paper
• Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy

  2014cited by this paper
• Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

  2013cited by this paper
• U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

  2013cited by this paper
• Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.

  2013cited by this paper
• Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

  2013cited by this paper
• Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

  2013cited by this paper
• A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

  2013cited by this paper
• Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma

  2013cited by this paper
• USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis

  2013cited by this paper
• Inhibition of Protein Deubiquitination by PR-619 Activates the Autophagic Pathway in OLN-t40 Oligodendroglial Cells

  2013cited by this paper
• Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.

  2013cited by this paper
• From bortezomib to other inhibitors of the proteasome and beyond.

  2013cited by this paper
• The lysine48-based polyubiquitin chain proteasomal signal: not a single child anymore.

  2013cited by this paper
• Manadosterols A and B, sulfonated sterol dimers inhibiting the Ubc13-Uev1A interaction, isolated from the marine sponge Lissodendryx fibrosa.

  2012cited by this paper
• A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.

  2012cited by this paper
• Proteasome inhibitors: an expanding army attacking a unique target.

  2012cited by this paper
• Erioflorin Stabilizes the Tumor Suppressor Pdcd4 by Inhibiting Its Interaction with the E3-ligase β-TrCP1

  2012cited by this paper
• A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

  2012cited by this paper
• The 26S proteasome complex: an attractive target for cancer therapy.

  2012cited by this paper
• The small molecule inhibitor PR-619 of deubiquitinating enzymes affects the microtubule network and causes protein aggregate formation in neural cells: implications for neurodegenerative diseases.

  2012cited by this paper
• Triggering Fbw7-Mediated Proteasomal Degradation of c-Myc by Oridonin Induces Cell Growth Inhibition and Apoptosis

  2012cited by this paper
• Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells

  2011cited by this paper
• Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes.

  2011cited by this paper
• Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases

  2011cited by this paper
• Novel proteasome inhibitors to overcome bortezomib resistance.

  2011cited by this paper
• In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells

  2011cited by this paper
• Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma

  2011cited by this paper
• Carfilzomib: a novel second-generation proteasome inhibitor.

  2011cited by this paper
• Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.

  2011cited by this paper
• An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme.

  2011cited by this paper
• RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis

  2011cited by this paper
• Ubiquitin networks in cancer.

  2011cited by this paper
• Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

  2011cited by this paper
• Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

  2011cited by this paper
• The therapeutic potential of deubiquitinating enzyme inhibitors.

  2010cited by this paper
• PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.

  2010cited by this paper
• Identification and Characterization of the First Small Molecule Inhibitor of MDMX*

  2010cited by this paper
• A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis

  2010cited by this paper
• Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.

  2010cited by this paper
• Degrasyn Potentiates the Antitumor Effects of Bortezomib in Mantle Cell Lymphoma Cells In vitro and In vivo: Therapeutic Implications

  2010cited by this paper
• Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.

  2010cited by this paper
• The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.

  2010cited by this paper
• Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.

  2010cited by this paper
• Identification of a Primary Target of Thalidomide Teratogenicity

  2010cited by this paper
• A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.

  2010cited by this paper
• Bortezomib‐induced apoptosis in mature T‐cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl‐1

  2009cited by this paper
• Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells

  2009cited by this paper
• Lysine 63‐linked polyubiquitin chain may serve as a targeting signal for the 26S proteasome

  2009cited by this paper
• Breaking the chains: structure and function of the deubiquitinases

  2009cited by this paper
• Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

  2009cited by this paper
• Involvement of linear polyubiquitylation of NEMO in NF-κB activation

  2009cited by this paper
• Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.

  2008cited by this paper
• Polyubiquitin chains: functions, structures, and mechanisms

  2008cited by this paper
• Novel substrates and functions for the ubiquitin-like molecule NEDD8.

  2008cited by this paper
• Leucettamol A: a new inhibitor of Ubc13-Uev1A interaction isolated from a marine sponge, Leucetta aff. microrhaphis.

  2008cited by this paper
• NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.

  2007cited by this paper
• Concise Review: Role and Function of the Ubiquitin‐Proteasome System in Mammalian Stem and Progenitor Cells

  2007cited by this paper
• UBE1L2, a Novel E1 Enzyme Specific for Ubiquitin*♦

  2007cited by this paper
• The ubiquitination code: a signalling problem

  2007cited by this paper
• 20S proteasome and its inhibitors: crystallographic knowledge for drug development.

  2007cited by this paper
• Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

  2007cited by this paper
• Ubiquitin ligases: cell-cycle control and cancer

  2006cited by this paper
• The polycomb protein Ring1B generates self atypical mixed ubiquitin chains required for its in vitro histone H2A ligase activity.

  2006cited by this paper
• Proteasome inhibitors in lung cancer.

  2006cited by this paper
• Itch/AIP4 mediates Deltex degradation through the formation of K29‐linked polyubiquitin chains

  2006cited by this paper
• Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

  2006cited by this paper
• Site-specific Lys-63-linked Tumor Necrosis Factor Receptor-associated Factor 6 Auto-ubiquitination Is a Critical Determinant of IκB Kinase Activation*

  2006cited by this paper
• Drug discovery in the ubiquitin–proteasome system

  2006cited by this paper
• MDMX Overexpression Prevents p53 Activation by the MDM2 Inhibitor Nutlin*

  2006cited by this paper
• Dissecting the ubiquitin pathway by mass spectrometry.

  2006cited by this paper
• Ubiquitin and ubiquitin-like modifications of the p53 family.

  2006cited by this paper
• Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

  2005cited by this paper
• Regulating the regulators: control of protein ubiquitination and ubiquitin-like modifications by extracellular stimuli.

  2005cited by this paper
• Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

  2005cited by this paper
• Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

  2005cited by this paper
• Proteolysis: from the lysosome to ubiquitin and the proteasome

  2005cited by this paper
• A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.

  2005cited by this paper
• The proteasome: a suitable antineoplastic target

  2004cited by this paper
• Ubiquitin-proteasome system

  2004cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• Development of the Proteasome Inhibitor Velcade™ (Bortezomib)

  2004cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• A proteomics approach to understanding protein ubiquitination

  2003cited by this paper

• Long noncoding RNAs in ubiquitination, protein degradation, and human diseases.

  2024cites this paper
• Potential roles of NEDD4 and NEDD4L and their utility as therapeutic targets in high‑incidence adult male cancers (Review)

  2023cites this paper
• UBA1 inhibition contributes radiosensitization of glioblastoma cells via blocking DNA damage repair

  2023cites this paper
• The ubiquitin‐proteasome system in melanin metabolism

  2022cites this paper
• CRISPR-Cas9 Screen Reveals PSMB3 Contributes to Gliomagenesis Through Proteasome-Dependent and Independent Mechanisms

  2021cites this paper
• SAV1, regulated by HERC4, inhibits the proliferation, migration, and invasion of hepatocellular carcinoma

  2021cites this paper
• Ubiquitin–proteasome system-targeted therapy for uveal melanoma: what is the evidence?

  2020cites this paper
• Ubiquitin ligases and medulloblastoma: genetic markers of the four consensus subgroups identified through transcriptome datasets.

  2020cites this paper
• Exploring the RC-106 Chemical Space: Design and Synthesis of Novel (E)-1-(3-Arylbut-2-en-1-yl)-4-(Substituted) Piperazine Derivatives as Potential Anticancer Agents

  2020cites this paper
• Ubiquitin–proteasome system-targeted therapy for uveal melanoma: what is the evidence?

  2020cites this paper
• Prognostic Value of SLC4A4 and its Correlation with Immune Infiltration in Colon Adenocarcinoma

  2020cites this paper
• Prolonged unfolded protein reaction is involved in the induction of CML cell death upon oprozomib treatment.

  2020cites this paper
• Prolonged unfolded protein reaction is involved in the induction of chronic myeloid leukemia cell death upon oprozomib treatment

  2020cites this paper
• Spatial transcriptomics identifies spatially dysregulated expression of GRM3 and USP47 in amyotrophic lateral sclerosis

  2020influential citation
• Scutellarein inhibits the development of colon cancer via CDC4-mediated RAGE ubiquitination

  2020cites this paper
• A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer

  2020cites this paper
• MiR-27a-3p Regulated the Aggressive Phenotypes of Cervical Cancer by Targeting FBXW7

  2020cites this paper
• Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas

  2019cites this paper
• Effects of ubiquitin-proteasome inhibitor on the expression levels of TNF-α and TGF-β1 in mice with viral myocarditis

  2019cites this paper
• Copy number variation is highly correlated with differential gene expression: a pan-cancer study

  2019cites this paper
• The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival

  2019cites this paper
• Ubiquitin specific peptidase 49 inhibits non‐small cell lung cancer cell growth by suppressing PI3K/AKT signaling

  2019cites this paper
• Structure and Function of the AAA+ ATPase p97, a Key Player in Protein Homeostasis.

  2019cites this paper
• Ginkgolic acid, a sumoylation inhibitor, promotes adipocyte commitment but suppresses adipocyte terminal differentiation of mouse bone marrow stromal cells

  2018cites this paper
• Design, synthesis, and biological evaluation of novel ubiquitin-activating enzyme inhibitors.

  2018cites this paper
• The Role of the Nuclear Factor κB Pathway in the Cellular Response to Low and High Linear Energy Transfer Radiation

  2018cites this paper
• The role of K63‐linked polyubiquitination in cardiac hypertrophy

  2018cites this paper
• Ubiquitination in Scleroderma Fibrosis and Its Treatment

  2018cites this paper
• Proteasome Activator 28γ: Impact on Survival Signaling and Apoptosis

  2018cites this paper
• inhibits the development of colon cancer via CDC4‑mediated RAGE ubiquitination

  year unknowncites this paper